Cargando…

Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion

The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs). Twenty-four patients with non–small cell lung cancer were ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Nan, Li, Fang, Li, Xiaosong, Kang, Huanrong, Zhao, Hui, Du, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134869/ https://www.ncbi.nlm.nih.gov/pubmed/27893676 http://dx.doi.org/10.1097/MD.0000000000005392

Ejemplares similares

Diagnostic value of pleural fluid SMRP, CA125, MMP-7, and MMP-9 in malignant pleural effusion
por: Han, Gaohua, et al.
Publicado: (2023)

Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report
por: Jiang, Sujing, et al.
Publicado: (2017)

Pleural small cell carcinoma with massive pleural effusion: A case report
por: Jang, Jong Geol, et al.
Publicado: (2019)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

The clinical efficacy of traditional Chinese medicine in the treatment of malignant pleural effusion: A protocol of systematic review and meta-analysis
por: Lin, Zhen, et al.
Publicado: (2020)

Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
por: Wang, Jian, et al.
Publicado: (2022)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis
por: Huang, Peng, et al.
Publicado: (2023)

Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion
por: Shan, Yi, et al.
Publicado: (2017)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion
por: Zhang, Fan, et al.
Publicado: (2019)

Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion
por: Chen, Kuan-Yuan, et al.
Publicado: (2016)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study
por: Hu, Nan, et al.
Publicado: (2015)

Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study
por: Ma, Junxun, et al.
Publicado: (2015)

TCM therapies combined with chemotherapy for preventing recurrence and metastasis in postoperative II to IIIA NSCLC: A protocol for a systematic review and meta-analysis
por: Chen, Shuntai, et al.
Publicado: (2019)

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis
por: Li, Juan, et al.
Publicado: (2020)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review
por: Jing, Xu-Quan, et al.
Publicado: (2016)

A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient: A case report
por: Fang, Yueyu, et al.
Publicado: (2021)

Clinical and pathology analysis of 1 case of adult pleural pulmonary blastoma: A case report
por: Liu, Yi, et al.
Publicado: (2017)

Diagnostic value of microRNA-148/152 family in non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis
por: Cheng, Long, et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study
por: Sugiyama, Keiji, et al.
Publicado: (2019)

Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis
por: Zhang, Wen, et al.
Publicado: (2021)

Management of Malignant Pleural Effusions
por: Villanueva, Andrew G.
Publicado: (2012)

Management of Malignant Pleural Effusions
por: Charpidou, Adrianni, et al.
Publicado: (2006)

Ambulatory Thoracoscopic Pleurodesis Combined With Indwelling Pleural Catheter in Malignant Pleural Effusion
por: Foo, Chuan T., et al.
Publicado: (2021)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients
por: Tang, Cuiping, et al.
Publicado: (2022)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
por: Chen, Jiakuan, et al.
Publicado: (2023)

Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma
por: Huang, DanHui, et al.
Publicado: (2023)

High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion
por: Yi, Fengshuang, et al.
Publicado: (2019)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Recent death early warning value of ECG changes in patients with NSCLC
por: Liu, Qiong, et al.
Publicado: (2023)

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report
por: Liang, Jin-Yan, et al.
Publicado: (2017)

The Efficacy and Toxicity of Paclitaxel Plus S-1 Compared With Paclitaxel Plus 5-Fu for Advanced Gastric Cancer: A PRISMA Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Liu, Huan, et al.
Publicado: (2014)

Clinical course of non-small cell lung cancer patients with dry pleural dissemination: Retrospective observational study
por: Kim, Woojung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_52kd3c3uv53p5cd9m418ia0kd2